Astellas Pharma Crescita futura
Criteri Future verificati 0/6
Si prevede che il fatturato e gli utili di Astellas Pharma diminuiscano rispettivamente di 7% e 12.7% all'anno. Si prevede che l'EPS diminuisca di 13.8% all'anno. Il rendimento del capitale proprio è previsto a 12.1% tra 3 anni.
Informazioni chiave
-12.7%
Tasso di crescita degli utili
-13.77%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 12.5% |
| Tasso di crescita dei ricavi | -7.0% |
| Rendimento futuro del capitale proprio | 12.13% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 17 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Articolo di analisi • Aug 08
Astellas Pharma Inc. Just Recorded A 55% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Astellas Pharma Inc. ( TSE:4503 ) came out with a strong set of first-quarter numbers that could...Articolo di analisi • Apr 30
Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Astellas Pharma Inc. ( TSE:4503 ) shareholders are probably feeling a little disappointed, since its shares fell 7.8...Articolo di analisi • Feb 08
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Astellas Pharma Inc. ( TSE:4503 ) defied analyst predictions to release its quarterly results, which were ahead of...Recent updates
Articolo di analisi • Aug 08
Astellas Pharma Inc. Just Recorded A 55% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Astellas Pharma Inc. ( TSE:4503 ) came out with a strong set of first-quarter numbers that could...
Aggiornamento narrativa • Aug 05
4503: Oncology Approvals And Trial Updates Will Drive Future Upside Potential
Analysts have raised their price target for Astellas Pharma from ¥2,950 to about ¥3,098, reflecting updated assumptions around slightly less revenue decline, a modestly lower profit margin, and a higher future P/E multiple. What's in the News Astellas Pharma and Pfizer received U.S. FDA approval for PADCEV plus Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle invasive bladder cancer, regardless of cisplatin eligibility, based on Phase 3 EV-304 data presented at the 2026 ASCO Genitourinary Cancers Symposium.Articolo di analisi • Jun 23
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Even though Astellas Pharma Inc.'s ( TSE:4503 ) recent earnings release was robust, the market didn't seem to notice...
Aggiornamento narrativa • Jun 23
4503: KRAS Oncology And AI Overhaul Will Likely Strain Future Returns
The latest analyst update on Astellas Pharma edges the fair value estimate from ¥1,669.63 to ¥1,701.65, with the modest change tied to revised assumptions on revenue trends, profit margins, and projected future P/E levels. What’s in the News for Astellas Pharma Astellas Pharma is internalizing clinical operations and adopting artificial intelligence tools in drug development, with a focus on improving clinical trial efficiency and decision making.Aggiornamento narrativa • Jun 07
4503: CSP2026 Oncology Pipeline And Dividends Will Drive Future Upside Potential
Analysts are holding their ¥2,950 price target for Astellas Pharma, with updated assumptions indicating softer revenue growth, higher profit margins, and a lower future P/E, which together help support the unchanged valuation. What's in the News Astellas announced its five year Corporate Strategic Plan "CSP2026," targeting 10 or more Phase 3 or pivotal studies by fiscal 2030 and aiming to double revenue from its Strategic Brands, with an objective of record high revenue in the mid 2030s and ongoing annual dividend increases (source: Astellas CSP2026 announcement).Aggiornamento narrativa • May 24
4503: Rising Bladder Cancer Setback Risks Will Likely Pressure Future Returns
Astellas Pharma's analyst price target has shifted from a fair value of ¥1,500 to about ¥1,670 as analysts factor in a higher assumed discount rate, softer revenue and profit expectations, and a higher future P/E multiple in their updated models. What's in the News Astellas plans to present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, including a 3.5-year follow up from the Phase 3 EV-302 study of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer, along with multiple prostate cancer and vasomotor symptom studies.
Aggiornamento narrativa • May 02
4503: Bladder Cancer Progress And Updated Guidance Will Shape Fairly Balanced Outlook
Analysts have slightly reduced their fair value estimate for Astellas Pharma from about ¥2,407 to about ¥2,396, citing updated assumptions that include a softer revenue outlook, a higher projected profit margin, and a lower future P/E multiple. What's in the News Astellas and Pfizer reported positive Phase 3 EV-304 data for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) in muscle invasive bladder cancer, with the regimen linked to a 47% lower risk of tumor recurrence, progression or death and a 35% lower risk of death compared with standard chemotherapy, along with a higher pathological complete response rate and no new safety signals (Key Developments).Articolo di analisi • Apr 30
Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Astellas Pharma Inc. ( TSE:4503 ) shareholders are probably feeling a little disappointed, since its shares fell 7.8...Aggiornamento narrativa • Apr 17
4503: Bladder Cancer Data And Guidance Will Temper Risks From Weaker Legacy Portfolio
Analysts have nudged their fair value estimate for Astellas Pharma higher from ¥2,100 to about ¥2,407, citing updated assumptions for revenue trends, profit margins, and a slightly lower future P/E multiple. What's in the News Astellas and HOVON reported that the Phase 3 HOVON 156 / AMLSG 28-18 / PASHA study of XOSPATA (gilteritinib) versus midostaurin-based treatment in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, with Astellas indicating it expects a minor impact on financial results for the fiscal year ending March 31, 2026 (Key Developments).Aggiornamento narrativa • Apr 02
4503: Future Oncology Pipeline And Partnerships Will Support Upside Potential
The analyst price target for Astellas Pharma has been revised from ¥2,700 to ¥2,950, with analysts citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple as key drivers behind the change. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, and Astellas plans a full data review and expects only a minor impact on fiscal 2026 results.Aggiornamento narrativa • Mar 19
4503: Trial Setbacks And Weaker Margins Will Likely Pressure Future Returns
Analysts have kept Astellas Pharma's fair value estimate steady at ¥1,500, while slightly adjusting assumptions for discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power, without changing the overall price target level. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint.Aggiornamento narrativa • Mar 05
4503: Bladder Cancer Pipeline Dependence Will Increase Execution Risk Versus Weakening Revenue Outlook
Astellas Pharma's analyst price target has been adjusted from ¥1,938 to ¥2,100, with analysts pointing to updated assumptions around a slightly higher discount rate, softer revenue growth, a modestly stronger profit margin and a higher future P/E multiple to support the new view. What's in the News Pfizer and Astellas reported positive Phase 3 EV-304 results for PADCEV in combination with Keytruda in muscle invasive bladder cancer.Aggiornamento narrativa • Feb 19
4503: Revised Earnings Outlook And Clinical Progress Will Support Balanced Future Upside
Analysts have adjusted their view on Astellas Pharma, raising the price target from ¥2,400 to ¥2,700, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Astellas revised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, with similar revisions on a full basis.Articolo di analisi • Feb 08
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Astellas Pharma Inc. ( TSE:4503 ) defied analyst predictions to release its quarterly results, which were ahead of...Aggiornamento narrativa • Feb 05
4503: Elevated Earnings Outlook Will Likely Mask Higher Long Term Margin Risks
Analysts have increased their fair value estimate for Astellas Pharma from ¥1,300 to ¥1,500, citing updated assumptions that include a revised revenue growth profile, higher projected profit margins, and a lower anticipated future P/E multiple. What's in the News Astellas raised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, supported by XTANDI and mirabegron products and foreign exchange effects (Key Developments).Articolo di analisi • Feb 05
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...Aggiornamento narrativa • Jan 22
4503: Rising Bladder Cancer Reliance Will Increase Execution Risk Versus Softer Revenue Outlook
Analysts have nudged their fair value estimate for Astellas Pharma up from ¥1,884.62 to ¥1,938.46, citing updated assumptions around slightly softer revenue growth, a modestly higher profit margin, and a small adjustment to the future P/E multiple. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, which keeps attention on deal activity in ophthalmology and broader specialty pharma (Investor's Business Daily).Articolo di analisi • Jan 19
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend on the 3rd of June, with...Aggiornamento narrativa • Jan 07
4503: Rising Bladder Cancer Pipeline Reliance Will Increase Execution And Partnering Risks
Analysts have modestly raised their fair value estimate for Astellas Pharma from ¥1,792.14 to ¥1,884.62, citing updated assumptions around slightly softer revenue contraction, a higher profit margin outlook, and a small adjustment to the future P/E multiple. What's in the News The U.S. FDA approved PADCEV in combination with Keytruda as perioperative treatment for adult patients with muscle invasive bladder cancer who are ineligible for cisplatin chemotherapy.Articolo di analisi • Jan 05
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) will pay a dividend of ¥39.00 on the 3rd of June. This makes the dividend yield 3.7...Articolo di analisi • Dec 17
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...Aggiornamento narrativa • Dec 14
4503: Early Veeva CRM Adoption Will Support Margin Expansion And Upside Potential
Analysts have nudged their price target on Astellas Pharma higher from ¥2,200 to ¥2,400, citing the company’s role among leading pharma adopters of Veeva’s upgraded CRM platform and a modestly improved long term profit margin outlook, despite slightly softer revenue growth assumptions. Analyst Commentary Bullish analysts point to Astellas Pharma’s early adoption of Veeva’s Vault CRM as a key validation of its digital commercial strategy, aligning the company with a growing roster of large global biopharma peers migrating to the upgraded platform.Articolo di analisi • Dec 03
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd of June...Aggiornamento narrativa • Nov 29
4503: Major Partner Platform Commitments Will Shape Competitive Positioning And Execution Risks
Analysts have slightly raised their price target for Astellas Pharma to ¥1,792.14 from ¥1,774.29. They cite continued incremental commitments from major industry partners as a supportive factor for the company's outlook.Aggiornamento narrativa • Nov 15
4503: Digital Transformation Commitments Will Drive Operational Efficiency And Execution Risk Ahead
Astellas Pharma's fair value target has been raised slightly from ¥1,753 to ¥1,774. This reflects analysts' expectations of improved revenue and margin trends in light of a renewed commitment to digital transformation within the sector.Articolo di analisi • Nov 07
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
When companies post strong earnings, the stock generally performs well, just like Astellas Pharma Inc.'s ( TSE:4503...Articolo di analisi • Nov 03
Astellas Pharma Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Astellas Pharma Inc. ( TSE:4503 ) just kicked off its latest half-yearly results with some very...Aggiornamento narrativa • Nov 01
4503: Digital CRM Adoption And Margin Pressures Will Shape Medium-Term Performance
Analysts have revised their price target for Astellas Pharma to ¥1,752.86, citing a more cautious outlook on revenue growth and margin pressures. This update reflects recent industry research and changes in competitive dynamics.Aggiornamento narrativa • Oct 17
Oncology And Rare Diseases Trends Will Unlock Global Potential
Astellas Pharma's analyst price target has increased slightly from ¥1,749.29 to ¥1,752.86. Analysts cite ongoing partnerships with industry leaders and an improved outlook on core platform adoption as contributing factors.Aggiornamento narrativa • Oct 03
Oncology And Rare Diseases Trends Will Unlock Global Potential
Analysts have raised their price target for Astellas Pharma from ¥1,725 to ¥1,749, citing steady fundamentals and ongoing industry commitments. These points were highlighted in recent sector developments.Articolo di analisi • Sep 19
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Aggiornamento narrativa • Sep 18
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a further decline in consensus revenue growth forecasts, Astellas Pharma’s analyst price target inched up from ¥1708 to ¥1725, reflecting only a marginal increase in perceived fair value. What's in the News Positive Phase 3 results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin; significant improvement in event-free and overall survival compared to surgery alone, with consistent safety profiles.Aggiornamento narrativa • Aug 27
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a notable improvement in consensus revenue growth forecasts, Astellas Pharma’s fair value was revised only slightly lower, with the analyst price target decreasing marginally from ¥1711 to ¥1692. What's in the News Positive Phase 3 EV-303 trial results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer show clinically meaningful improvements in event-free and overall survival versus surgery alone.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2029 | 1,896,709 | 252,140 | 467,072 | 543,252 | 12 |
| 3/31/2028 | 2,136,534 | 332,560 | 515,896 | 594,334 | 13 |
| 3/31/2027 | 2,315,496 | 355,833 | 436,239 | 523,855 | 13 |
| 6/30/2026 | 2,274,365 | 364,941 | 464,828 | 591,827 | N/A |
| 3/31/2026 | 2,139,245 | 291,535 | 475,543 | 560,188 | N/A |
| 12/31/2025 | 2,043,974 | 294,481 | 443,843 | 522,469 | N/A |
| 9/30/2025 | 2,006,816 | 124,871 | 334,836 | 399,700 | N/A |
| 6/30/2025 | 1,944,993 | 81,566 | 189,328 | 236,749 | N/A |
| 3/31/2025 | 1,912,323 | 50,747 | 138,341 | 194,512 | N/A |
| 12/31/2024 | 1,867,631 | -57,427 | 101,141 | 165,416 | N/A |
| 9/30/2024 | 1,772,155 | 54,746 | 125,654 | 200,804 | N/A |
| 6/30/2024 | 1,701,806 | 21,519 | 92,795 | 172,877 | N/A |
| 3/31/2024 | 1,603,672 | 17,045 | 100,981 | 172,475 | N/A |
| 12/31/2023 | 1,543,324 | 4,198 | 136,404 | 216,089 | N/A |
| 9/30/2023 | 1,523,572 | 38,090 | 151,562 | 236,992 | N/A |
| 6/30/2023 | 1,511,818 | 107,031 | 205,852 | 291,133 | N/A |
| 3/31/2023 | 1,518,619 | 98,714 | 239,438 | 327,767 | N/A |
| 12/31/2022 | 1,468,235 | 136,430 | 183,399 | 260,759 | N/A |
| 9/30/2022 | 1,406,682 | 148,911 | 214,107 | 257,916 | N/A |
| 6/30/2022 | 1,351,811 | 118,211 | 215,849 | 266,193 | N/A |
| 3/31/2022 | 1,296,163 | 124,086 | 205,277 | 257,444 | N/A |
| 12/31/2021 | 1,300,914 | 120,167 | 236,959 | 290,559 | N/A |
| 9/30/2021 | 1,285,714 | 119,360 | 248,993 | 331,268 | N/A |
| 6/30/2021 | 1,268,702 | 100,863 | 261,235 | 325,326 | N/A |
| 3/31/2021 | 1,249,528 | 120,589 | 229,402 | 306,843 | N/A |
| 12/31/2020 | 1,253,215 | 138,307 | 196,679 | 276,851 | N/A |
| 9/30/2020 | 1,265,853 | 139,722 | 146,751 | 235,299 | N/A |
| 6/30/2020 | 1,273,678 | 187,306 | 135,534 | 236,186 | N/A |
| 3/31/2020 | 1,300,843 | 195,411 | N/A | 221,998 | N/A |
| 12/31/2019 | 1,289,855 | 220,751 | N/A | 225,239 | N/A |
| 9/30/2019 | 1,309,722 | 246,925 | N/A | 248,203 | N/A |
| 6/30/2019 | 1,311,397 | 226,224 | N/A | 228,863 | N/A |
| 3/31/2019 | 1,306,348 | 222,265 | N/A | 258,630 | N/A |
| 12/31/2018 | 1,305,901 | 213,600 | N/A | 300,955 | N/A |
| 9/30/2018 | 1,307,658 | 186,429 | N/A | 309,442 | N/A |
| 6/30/2018 | 1,306,830 | 176,770 | N/A | 290,301 | N/A |
| 3/31/2018 | 1,300,316 | 164,679 | N/A | 312,614 | N/A |
| 12/31/2017 | 1,305,521 | 182,515 | N/A | 264,549 | N/A |
| 9/30/2017 | 1,299,746 | 185,754 | N/A | 260,795 | N/A |
| 6/30/2017 | 1,296,484 | 194,556 | N/A | 276,954 | N/A |
| 3/31/2017 | 1,311,665 | 218,701 | N/A | 235,612 | N/A |
| 12/31/2016 | 1,312,627 | 207,940 | N/A | 325,459 | N/A |
| 9/30/2016 | 1,336,878 | 205,818 | N/A | 308,800 | N/A |
| 6/30/2016 | 1,366,799 | 215,678 | N/A | 302,245 | N/A |
| 3/31/2016 | 1,372,706 | 193,687 | N/A | 313,737 | N/A |
| 12/31/2015 | 1,360,153 | 185,659 | N/A | 207,806 | N/A |
| 9/30/2015 | 1,340,307 | 168,805 | N/A | 182,815 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che gli utili di 4503 diminuiranno nei prossimi 3 anni ( -12.7% all'anno).
Guadagni vs Mercato: Si prevede che gli utili di 4503 diminuiranno nei prossimi 3 anni ( -12.7% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di 4503 diminuiranno nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che i ricavi di 4503 diminuiranno nei prossimi 3 anni ( -7% all'anno).
Ricavi ad alta crescita: Si prevede che i ricavi di 4503 diminuiranno nei prossimi 3 anni ( -7% all'anno).
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di 4503 sarà basso tra 3 anni ( 12.1 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/19 19:24 |
| Prezzo dell'azione a fine giornata | 2026/08/19 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Astellas Pharma Inc. è coperta da 24 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |